Drug repurposing for anticancer therapies. A lesson from proton pump inhibitors

Enrico Pierluigi Spugnini, Stefano Fais

Research output: Contribution to journalArticle

Abstract

Introduction: Worldwide, the annual expenditure on anticancer drugs is grossly calculated to be in the order of US$100 billion, and is expected to escalate up to $150 billion by 2020. It is evident that the vast majority of the most recently devised anticancer drugs are unaffordable in economically developing nations, frequently resulting in subpar therapies. In this complex medical and economic scenario, the repurposing of older drugs for anticancer therapies becomes a necessity. The repurposing of antiacid drugs such as the proton pump inhibitors as antitumoral agents and chemosensitizers is probably one of the most recent and promising phenomenon in oncology. Areas covered: Important research articles and patents focusing on proton pump inhibitors as a potential class of therapeutics, published between the period of 2006–2019, have been covered. This review mainly focuses on the therapeutic applications, as direct anticancer agents as well as modifiers of the tumor microenvironment and modulator of chemoresistance. Expert opinion: PPIs have significant anticancer applications and are proving to be safe, effective and inexpensive. Here the authors review the current knowledge regarding the influence of PPIs on the efficacy and safety of cancer chemotherapeutics through the regulation of targets other than the H+/K+-ATPase.

Original languageEnglish
Pages (from-to)15-25
Number of pages11
JournalExpert Opinion on Therapeutic Patents
Volume30
Issue number1
DOIs
Publication statusPublished - Jan 2 2020

Fingerprint

Drug Repositioning
Proton Pump Inhibitors
Medical Economics
Proton-Translocating ATPases
Tumor Microenvironment
Patents
Expert Testimony
Health Expenditures
Pharmaceutical Preparations
Antineoplastic Agents
Developing Countries
Therapeutics
Safety
Drug Therapy
Research
Neoplasms

Keywords

  • Acidity
  • chemotherapy
  • pH
  • proton pump inhibitors
  • resistance to drugs
  • tumors

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

Drug repurposing for anticancer therapies. A lesson from proton pump inhibitors. / Spugnini, Enrico Pierluigi; Fais, Stefano.

In: Expert Opinion on Therapeutic Patents, Vol. 30, No. 1, 02.01.2020, p. 15-25.

Research output: Contribution to journalArticle

@article{ab9c29c581d54d1c9d34598d61cd9126,
title = "Drug repurposing for anticancer therapies. A lesson from proton pump inhibitors",
abstract = "Introduction: Worldwide, the annual expenditure on anticancer drugs is grossly calculated to be in the order of US$100 billion, and is expected to escalate up to $150 billion by 2020. It is evident that the vast majority of the most recently devised anticancer drugs are unaffordable in economically developing nations, frequently resulting in subpar therapies. In this complex medical and economic scenario, the repurposing of older drugs for anticancer therapies becomes a necessity. The repurposing of antiacid drugs such as the proton pump inhibitors as antitumoral agents and chemosensitizers is probably one of the most recent and promising phenomenon in oncology. Areas covered: Important research articles and patents focusing on proton pump inhibitors as a potential class of therapeutics, published between the period of 2006–2019, have been covered. This review mainly focuses on the therapeutic applications, as direct anticancer agents as well as modifiers of the tumor microenvironment and modulator of chemoresistance. Expert opinion: PPIs have significant anticancer applications and are proving to be safe, effective and inexpensive. Here the authors review the current knowledge regarding the influence of PPIs on the efficacy and safety of cancer chemotherapeutics through the regulation of targets other than the H+/K+-ATPase.",
keywords = "Acidity, chemotherapy, pH, proton pump inhibitors, resistance to drugs, tumors",
author = "Spugnini, {Enrico Pierluigi} and Stefano Fais",
year = "2020",
month = "1",
day = "2",
doi = "10.1080/13543776.2020.1704733",
language = "English",
volume = "30",
pages = "15--25",
journal = "Expert Opinion on Therapeutic Patents",
issn = "1354-3776",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Drug repurposing for anticancer therapies. A lesson from proton pump inhibitors

AU - Spugnini, Enrico Pierluigi

AU - Fais, Stefano

PY - 2020/1/2

Y1 - 2020/1/2

N2 - Introduction: Worldwide, the annual expenditure on anticancer drugs is grossly calculated to be in the order of US$100 billion, and is expected to escalate up to $150 billion by 2020. It is evident that the vast majority of the most recently devised anticancer drugs are unaffordable in economically developing nations, frequently resulting in subpar therapies. In this complex medical and economic scenario, the repurposing of older drugs for anticancer therapies becomes a necessity. The repurposing of antiacid drugs such as the proton pump inhibitors as antitumoral agents and chemosensitizers is probably one of the most recent and promising phenomenon in oncology. Areas covered: Important research articles and patents focusing on proton pump inhibitors as a potential class of therapeutics, published between the period of 2006–2019, have been covered. This review mainly focuses on the therapeutic applications, as direct anticancer agents as well as modifiers of the tumor microenvironment and modulator of chemoresistance. Expert opinion: PPIs have significant anticancer applications and are proving to be safe, effective and inexpensive. Here the authors review the current knowledge regarding the influence of PPIs on the efficacy and safety of cancer chemotherapeutics through the regulation of targets other than the H+/K+-ATPase.

AB - Introduction: Worldwide, the annual expenditure on anticancer drugs is grossly calculated to be in the order of US$100 billion, and is expected to escalate up to $150 billion by 2020. It is evident that the vast majority of the most recently devised anticancer drugs are unaffordable in economically developing nations, frequently resulting in subpar therapies. In this complex medical and economic scenario, the repurposing of older drugs for anticancer therapies becomes a necessity. The repurposing of antiacid drugs such as the proton pump inhibitors as antitumoral agents and chemosensitizers is probably one of the most recent and promising phenomenon in oncology. Areas covered: Important research articles and patents focusing on proton pump inhibitors as a potential class of therapeutics, published between the period of 2006–2019, have been covered. This review mainly focuses on the therapeutic applications, as direct anticancer agents as well as modifiers of the tumor microenvironment and modulator of chemoresistance. Expert opinion: PPIs have significant anticancer applications and are proving to be safe, effective and inexpensive. Here the authors review the current knowledge regarding the influence of PPIs on the efficacy and safety of cancer chemotherapeutics through the regulation of targets other than the H+/K+-ATPase.

KW - Acidity

KW - chemotherapy

KW - pH

KW - proton pump inhibitors

KW - resistance to drugs

KW - tumors

UR - http://www.scopus.com/inward/record.url?scp=85077149701&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85077149701&partnerID=8YFLogxK

U2 - 10.1080/13543776.2020.1704733

DO - 10.1080/13543776.2020.1704733

M3 - Article

C2 - 31847622

AN - SCOPUS:85077149701

VL - 30

SP - 15

EP - 25

JO - Expert Opinion on Therapeutic Patents

JF - Expert Opinion on Therapeutic Patents

SN - 1354-3776

IS - 1

ER -